Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer

Clinical Cancer Research

Volumn 18, Issue 19, 2012, Pages 5314-5328

  Julien, Sylvia ^a   Merino Trigo, Ana ^b   Lacroix, Ludovic ^c   Pocard, Marc ^d   Goeŕé, Diane ^c   Mariani, Pascale ^e   Landron, Sophie ^f   Bigot, Ludovic ^c   Nemati, Fariba ^e   Dartigues, Peggy ^c   Weiswald, Louis Bastien ^g   Lantuas, Denis ^d   Morgand, Loïc ⁱ   Pham, Emmanuel ^a   Gonin, Patrick ^c   Dangles Marie, Virginie ^d,g   Job, Bastien ^c   Dessen, Philippe ^c   Bruno, Alain ^f   Pierré, Alain ^f   De Thé, Hugues ^h   Soliman, Hany ^h   Nunes, Manoel ^b   Lardier, Guillaume ^b   Calvet, Loreley ^b   Demers, Brigitte ^b   Prévost, Grégoire ^a   Vrignaud, Patricia ^b   Roman Roman, Sergio ^e   Duchamp, Olivier ⁱ   Berthet, Cyril ⁱ   more..

^a IPSEN   (France)

^b Sanofi Vitry sur Seine   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Hôpital Lariboisière   (France)

^e INSTITUT CURIE   (France)

^f INSTITUT DE RECHERCHES SERVIER   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITÉ PARIS DIDEROT   (France)

ⁱ Oncodesign   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APC GENE; CANCER INHIBITION; CANCER PATIENT; CANCER REGRESSION; CANCER STAGING; CELL HETEROGENEITY; CHEMOSENSITIVITY; CHROMOSOME ABERRATION; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISTANT METASTASIS; DRUG RESPONSE; EXON; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MICROSATELLITE INSTABILITY; MOUSE; NONHUMAN; NOTE; ONCOGENE K RAS; PERITONEUM CANCER; PHENOTYPE; PRIORITY JOURNAL; RAT; STROMA CELL; TP53 GENE; TRANSCRIPTOMICS; TUMOR GENE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, MONOCLONAL; CAMPTOTHECIN; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866923492     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0372     Document Type: Note

References (28)

1. Cree IA, Glaysher S, Harvey AL. Ef ficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 2010;10:375-9.
2. Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T, et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 2004;40:298-307. (Pubitemid 38077034)
3. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-20. (Pubitemid 38519759)
4. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011;10:1311-6.
5. Krumbach R, Schüler J, Hofmann M, Giesemann T, Fiebig H-H, Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011;47:1231-43.
6. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 2008;85:217-21.
7. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts ('xenopatients') identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508-23.
8. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011;17:1514-20.
9. Némati F, Sastre-Garau X, Laurent C, Couturier J, Mariani P, Desjardins L, et al. Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors. Clin Cancer Res 2010;16:2352-62.
10. Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res 2007;13:3989-98. (Pubitemid 47037607)
11. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
12. Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, et al. Evaluation of tumor microsatellite instability using five quasimonomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123:1804-11. (Pubitemid 35408304)
13. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8. (Pubitemid 38256271)
14. Olshen AB, Venkatraman ES, Lucito R, Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-72. (Pubitemid 41180205)
15. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, Lu YT, et al. The UCSC genome browser database. Nucleic Acids Res 2003;31:51-4. (Pubitemid 36150331)
16. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 1982;42:1707-15. (Pubitemid 12103362)
17. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. New York: Chapman and Hall; 1984.
18. Boyle P, Leon ME. Epidemiology of colorectal cancer. Br Med Bull 2002;64:1-25. (Pubitemid 35238576)
19. Forbes SA, Bhamra G, Bamford S, Dawson E, Kok C, Clements J, et al. The catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum Genet 2008;Chapter 10:Unit 10.11.
20. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 1995;92:3963-7.
21. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009;69:1851-7.
22. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39. (Pubitemid 37204044)
23. Van Weerden WM, Bangma C, De Wit R. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer 2009;100:13-8.
24. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, et al. Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol 2009;3:469-82.
25. Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, et al. Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res 2012;14:R11.
26. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
27. Rothenberg ML. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin Oncol 1998;25:39-46. (Pubitemid 28478054)
28. O'Reilly T, McSheehy PM, Kawai R, Kretz O, McMahon L, Brueggen J, et al. Comparative pharmacokinetics of RAD001 (everolimus) in normal and tumor-bearing rodents. Cancer Chemother Pharmacol 2010;65:625-39.